Table 4.
Comparison between edematous myositis and dermatomyositis without edema
| Variables | DM without limb edema* | Edematous myositis | P‐value** |
|---|---|---|---|
| Median age at diagnosis | 45 [37.5; 57.5] | 52 [45.2; 58.7] | 1 |
| Female | 33 (66%) | 10 (58.8%) | 1 |
| CK level (UI/L | 1800 [893; 8304] | 5118 [1654; 6928] | 1 |
| Muscle weakness | 42 (84%) | 15 (88.2%) | 1 |
| Dysphagia | 28 (57.1%) | 12 (70.6%) | 1 |
| Cancer | 12 (24%) | 4 (25%) | 1 |
| Raynaud | 8 (16.3%) | 2 (11.76%) | 1 |
| Arthritis | 12 (25%) | 0 (0%) | 0.97 |
| Capillary C5b‐9 depositions | 26 (66.7%) | 13 (92.7%) | 1 |
| MCH class 1 expression | 31 (86.1%) | 14 (100%) | 1 |
| DM skin Rash | 40 (80%) | 9 (52.9%) | 0.97 |
| Gottron's papules | 21 (42%) | 4 (23.5%) | 1 |
| Periungueal erythema | 22 (44%) | 5 (29.4%) | 1 |
| Erythema of the eyelids | 8 (16%) | 5 (29.4%) | 1 |
| Flagellate erythema | 19 (38%) | 1 (5.9%) | 0.48 |
| Holster sign | 4 (8%) | 2 (11.8%) | 1 |
| Interstitial lung disease | 9 (18.7%) | 1 (5.9%) | 1 |
| MSA | |||
| MDA5 | 7 (14%) | 0 (0%) | 0.14 |
| Mi‐2 | 12 (24%) | 1 (5.9%) | |
| NXP2 | 3 (6%) | 2 (11.8%) | |
| NXP2‐SAE | 0 (0%) | 1 (5.9%) | |
| SAE | 2 (4%) | 1 (5.9%) | |
| TIF1γ | 3 (6%) | 3 (17.6%) | |
| Seronegative | 23 (46%) | 7 (41.2%) | 0.14 |
| Not done | 0 (0%) | 2 (11.8%) | 0.14 |
Italics denote significance values.
Abbreviations: DM = dermatomyositis; MSA = myositis specific antibodies.
*
n (%) or median [Q1; Q3].
**
Adjusted P‐value Benjamini Hochberg.